This is key to making it safe and effective.
The FDA has approved the first and only pill to prevent COVID-19 after exposure to the virus. Here's how it works. (Photo: ...
FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...
Ensitrelvir, marketed as Xocova, works by inhibiting viral replication and is designed as a 5-day oral protective regimen, ...
Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
A schematic diagram showing the significant contribution of SCoV2-induced altered mitochondrial dynamics and mitochondrial EGFR translocation in sustaining viral propagation. First, SCOV2 RNA and ...
A research team at Ruhr University Bochum, Germany, has identified a previously unknown cellular mechanism crucial to the replication of coronaviruses: c-Jun N-terminal kinase (JNK) is activated ...
OSAKA, Japan, June 01, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter "Shionogi") announced that the U.S. Food and ...
FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
According to an article published in the journal PLOS Pathogens, severe COVID-19 patients can be divided into two distinct groups: those with a high viral load and relatively little inflammation, and ...
What are antiviral treatments, how can you access them if you're eligible and how important are they in our pandemic response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results